CA2084659A1 - Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisations - Google Patents
Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisationsInfo
- Publication number
- CA2084659A1 CA2084659A1 CA002084659A CA2084659A CA2084659A1 CA 2084659 A1 CA2084659 A1 CA 2084659A1 CA 002084659 A CA002084659 A CA 002084659A CA 2084659 A CA2084659 A CA 2084659A CA 2084659 A1 CA2084659 A1 CA 2084659A1
- Authority
- CA
- Canada
- Prior art keywords
- hiv
- vector
- gene
- nucleotides
- sufficient number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013598 vector Substances 0.000 title claims abstract description 152
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 79
- 230000002950 deficient Effects 0.000 title abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 99
- 238000012546 transfer Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 124
- 239000002773 nucleotide Substances 0.000 claims description 78
- 125000003729 nucleotide group Chemical group 0.000 claims description 77
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 48
- 210000002845 virion Anatomy 0.000 claims description 46
- 230000008488 polyadenylation Effects 0.000 claims description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 21
- 230000003612 virological effect Effects 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108091081024 Start codon Proteins 0.000 claims description 15
- 108700004025 env Genes Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000011144 upstream manufacturing Methods 0.000 claims description 12
- 101150030339 env gene Proteins 0.000 claims description 10
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 108090000994 Catalytic RNA Proteins 0.000 claims description 3
- 102000053642 Catalytic RNA Human genes 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 108700004029 pol Genes Proteins 0.000 claims description 3
- 108010043277 recombinant soluble CD4 Proteins 0.000 claims description 3
- 108091092562 ribozyme Proteins 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 108700004030 rev Genes Proteins 0.000 claims description 2
- 101150098213 rev gene Proteins 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 108700004026 gag Genes Proteins 0.000 claims 8
- 101150098622 gag gene Proteins 0.000 claims 8
- 101710177291 Gag polyprotein Proteins 0.000 claims 2
- 102100034353 Integrase Human genes 0.000 claims 2
- 101710125418 Major capsid protein Proteins 0.000 claims 2
- 108010078428 env Gene Products Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101710150344 Protein Rev Proteins 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 108010089520 pol Gene Products Proteins 0.000 claims 1
- 101150088264 pol gene Proteins 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 6
- 241000700605 Viruses Species 0.000 description 32
- 239000006228 supernatant Substances 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 21
- 230000000692 anti-sense effect Effects 0.000 description 18
- 238000012217 deletion Methods 0.000 description 16
- 230000037430 deletion Effects 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 102100034349 Integrase Human genes 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 101710205625 Capsid protein p24 Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 101710177166 Phosphoprotein Proteins 0.000 description 11
- 101710149279 Small delta antigen Proteins 0.000 description 11
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 11
- 108020000999 Viral RNA Proteins 0.000 description 10
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 108010067390 Viral Proteins Proteins 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 241000713311 Simian immunodeficiency virus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000013592 cell lysate Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 5
- 241001068263 Replication competent viruses Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 101710121417 Envelope glycoprotein Proteins 0.000 description 4
- 108010025815 Kanamycin Kinase Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- RDJXPXHQENRCNG-UHFFFAOYSA-N 2-aminophenoxazin-3-one Chemical compound C1=CC=C2OC3=CC(=O)C(N)=CC3=NC2=C1 RDJXPXHQENRCNG-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 241001045988 Neogene Species 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 241000713675 Spumavirus Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 101150091879 neo gene Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 108700004027 tat Genes Proteins 0.000 description 2
- 101150098170 tat gene Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000003907 Cyclin I Human genes 0.000 description 1
- 108090000264 Cyclin I Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000713711 Primate lentivirus group Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 101710132316 Transactivation protein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 108010080511 serum sodium transport inhibitor Proteins 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000017960 syncytium formation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54074690A | 1990-06-20 | 1990-06-20 | |
| US540,746 | 1990-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2084659A1 true CA2084659A1 (fr) | 1991-12-21 |
Family
ID=24156769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002084659A Abandoned CA2084659A1 (fr) | 1990-06-20 | 1991-06-18 | Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0536234A4 (fr) |
| JP (1) | JP3264281B2 (fr) |
| CA (1) | CA2084659A1 (fr) |
| WO (1) | WO1991019798A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| DK0630409T3 (da) | 1992-02-28 | 2003-03-24 | Syngenix Ltd | Defekt-pakkende ikke-onkovirus-vektorer baseret på MPMV |
| AU678152B2 (en) * | 1992-03-27 | 1997-05-22 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| EP0644946A4 (fr) * | 1992-06-10 | 1997-03-12 | Us Health | Particules vecteurs resistantes a l'inactivation par le serum humain. |
| CA2154363A1 (fr) * | 1993-01-22 | 1994-08-04 | Bruce A. Sullenger | Localisation d'agents therapeutiques |
| US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5837464A (en) * | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US6200811B1 (en) * | 1996-04-02 | 2001-03-13 | The Regents Of The University Of California | Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein |
| US7198784B2 (en) | 1996-10-17 | 2007-04-03 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
| WO1998017815A1 (fr) * | 1996-10-17 | 1998-04-30 | Oxford Biomedica (Uk) Limited | Vecteurs retroviraux |
| CN1322137C (zh) | 1997-12-22 | 2007-06-20 | 牛津生物医学（英国）有限公司 | 基于马传染性贫血病毒(eiav)的逆转录病毒载体 |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| AU7268000A (en) * | 1999-07-21 | 2001-02-13 | Martin Heinkelein | Method for quantization of the antiviral effect of antiviral active principles |
| GB0108065D0 (en) * | 2001-03-30 | 2001-05-23 | Syngenix Ltd | Viral vectors |
| WO2005118809A2 (fr) * | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Procedes et compositions pour ameliorer les proprietes d'adhesion cellulaire |
-
1991
- 1991-06-18 CA CA002084659A patent/CA2084659A1/fr not_active Abandoned
- 1991-06-18 WO PCT/US1991/004335 patent/WO1991019798A1/fr not_active Application Discontinuation
- 1991-06-18 JP JP51128291A patent/JP3264281B2/ja not_active Expired - Lifetime
- 1991-06-18 EP EP19910912130 patent/EP0536234A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991019798A1 (fr) | 1991-12-26 |
| EP0536234A4 (en) | 1993-09-15 |
| JP3264281B2 (ja) | 2002-03-11 |
| EP0536234A1 (fr) | 1993-04-14 |
| JPH05508320A (ja) | 1993-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5665577A (en) | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof | |
| US5981276A (en) | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof | |
| CA2009403C (fr) | Provirus hiv a encapsidation defectueuse, lignees cellulaires et leur utilisation | |
| Parolin et al. | Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes | |
| Chesebro et al. | Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages | |
| Kondo et al. | The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles | |
| Srinivasakumar et al. | The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines | |
| Bray et al. | A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. | |
| Sodroski et al. | A second post-transcriptional trans-activator gene required for HTLV-III replication | |
| Malim et al. | Functional comparison of the Rev trans-activators encoded by different primate immunodeficiency virus species. | |
| Cheng-Mayer et al. | Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 | |
| Kornfeld et al. | Cloning of HTLV-4 and its relation to simian and human immunodeficiency viruses | |
| Reitz Jr et al. | Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene | |
| US6013516A (en) | Vector and method of use for nucleic acid delivery to non-dividing cells | |
| CA2084659A1 (fr) | Vecteurs contenant des sequences du vih aptes a l'encapsidation, vecteurs du vih inaptes a l'encapsidation et leurs utilisations | |
| Kim et al. | V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate | |
| US5747307A (en) | Mason-Pfizer Monkey Retroviral packaging defective vectors | |
| Etemad-Moghadam et al. | Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys | |
| Foster et al. | Specific suppression of human CD4 surface expression by Nef from the pathogenic simian immunodeficiency virus SIVmac239open | |
| Ndung'u et al. | Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model | |
| Pfeiffer et al. | Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells | |
| Talbott et al. | Mapping the determinants of human immunodeficiency virus 2 for infectivity, replication efficiency, and cytopathicity. | |
| Wong-Staal | The AIDS virus. What we know and what we can do about it. | |
| EP0535161A4 (en) | Expression vectors containing the hiv -i(nef) gene to enhance replication efficiency | |
| Contag et al. | Simian immunodeficiency virus (SIV) from Old World monkeys |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |